Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
2(17%)
Results Posted
33%(3 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
2
17%
Ph phase_4
2
17%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 42 (50.0%)
N/A2 (50.0%)

Trials by Status

completed975%
active_not_recruiting217%
terminated18%

Recent Activity

2 active trials
Showing 5 of 12
completed

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

NCT07332156
active_not_recruiting

SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

NCT07198191
completed

Empa PASS on Urinary Tract Malignancies

NCT03464045
completed

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

NCT02864914
active_not_recruitingnot_applicable

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT06611904
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07332156

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Completed
NCT07198191

SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

Active Not Recruiting
NCT03464045

Empa PASS on Urinary Tract Malignancies

Completed
NCT02864914

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Completed
NCT06611904Not Applicable

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Active Not Recruiting
NCT02244164Not Applicable

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Terminated
NCT02041234Phase 4

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Completed
NCT03486964

Use of Incretins in Diabetic Patients

Completed
NCT02730377Phase 4

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Completed
NCT02476760

Incretin-based Drugs and Acute Pancreatitis

Completed
NCT02456428

Incretin-based Drugs and the Risk of Heart Failure

Completed
NCT02475499

Incretin-based Drugs and Pancreatic Cancer

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12